Developing In Vitro-In Vivo Correlation (Ivivc) For Trimetazidine, Indapamide And Ciprofloxacin Extended-Release Solid Oral Dosage Forms

Authors

  • I. E. SHOHIN Sechenov First Moscow State Medical University, Moscow, Russia
  • G. V. RAMENSKAYA Sechenov First Moscow State Medical University, Moscow, Russia 2 Scientific Center for Biomedical Technologies RAMS, Moscow, Russia
  • A. Y. SAVCHENKO Scientific Center for Biomedical Technologies RAMS, Moscow, Russia

Keywords:

In vitro-in vivo correlation (IVIVC), dissolution, trimetazidine, indapamide, ciprofloxacin.

Abstract

The current paper describes in vitro-in vivo correlation (IVIVC) development for extended-release solid oral dosage forms containing BCS Class I, II and III APIs: trimetazidine, indapamide and ciprofloxacin. Dissolution kinetics (in 3 media: 0.1 M or 0.01 M hydrochloric acid, acetate buffer pH 4.3, phosphate buffer pH 6.8) and pharmacokinetic properties of evaluated drugs were studied. Level B IVIVC was established for each of evaluated solid oral dosage forms, correlation coefficients (r) were 0.97, 0.94 and 0.96 for trimetazidine, indapamide and ciprofloxacin drugs, respectively.

Downloads

Published

31.12.2011

How to Cite

I. E. SHOHIN, G. V. RAMENSKAYA, & A. Y. SAVCHENKO. (2011). Developing In Vitro-In Vivo Correlation (Ivivc) For Trimetazidine, Indapamide And Ciprofloxacin Extended-Release Solid Oral Dosage Forms. International Journal of Pharma and Bio Sciences, 2(4), 573–580. Retrieved from https://ijpbs.net/index.php/journal/article/view/1054

Issue

Volume 2, Issue 4, 2011

Section

Research Articles

Categories